{"url":"https://newsforagent.com/news/2026-11-18/lynch-regenerative-medicine-fda-inds-rhpdgf-bb","markdown_url":"https://newsforagent.com/news/2026-11-18/lynch-regenerative-medicine-fda-inds-rhpdgf-bb.md","title":"Lynch Regenerative Medicine Wins FDA Nod for Two rhPDGF-BB Trials","headline":"Lynch Regenerative Medicine Gains FDA Authorization for Two Investigator-Led rhPDGF-BB Studies","description":"Lynch Regenerative Medicine secured FDA authorization for two investigator-initiated INDs testing injectable rhPDGF-BB in 12 and 30 participants.","section":"Regulation & Approvals","published_at":"2026-11-18T14:29:46+00:00","modified_at":"2026-11-18T14:29:46+00:00","author":"News Desk","key_takeaways":["The FDA accepted two new investigator-initiated INDs for injectable rhPDGF-BB, one led by Michael Somenek, MD, and one by Sarah Allen, MD.","Somenek's study will biopsy facial skin in 12 participants at 7 days, 14 days, 28 days or 8 weeks to assess gene and protein expression.","Allen's study will evaluate safety and efficacy of undereye injections for infraorbital hollowing in 30 participants, with completion anticipated in Q3 2027."],"companies":[{"name":"Lynch Regenerative Medicine","is_primary":true,"profile_url":"https://akta.pro/company-profiles/00031g2/lynch-regenerative-medicine","website":"https://www.lynchregen.com"}],"source":{"publisher":"PR Newswire","title":"Lynch Regenerative Medicine (LRM) Announces FDA Authorization of Two New INDs For Investigator-Initiated Clinical Trials Evaluating Injectable rhPDGF-BB for Facial Skin Quality and Treatment of Infrao","url":"https://www.prnewswire.com/news-releases/lynch-regenerative-medicine-lrm-announces-fda-authorization-of-two-new-inds-for-investigator-initiated-clinical-trials-evaluating-injectable-rhpdgf-bb-for-facial-skin-quality-and-treatment-of-infraorbital-hollowing-302942954.html"},"other_sources":[],"tags":["Regulation & Approvals","Lynch Regenerative Medicine"],"body_markdown":"Lynch Regenerative Medicine said the U.S. Food and Drug Administration accepted two new investigator-initiated INDs for injectable recombinant human platelet-derived growth factor-BB (rhPDGF-BB) in regenerative aesthetics, [PR Newswire](https://www.prnewswire.com/news-releases/lynch-regenerative-medicine-lrm-announces-fda-authorization-of-two-new-inds-for-investigator-initiated-clinical-trials-evaluating-injectable-rhpdgf-bb-for-facial-skin-quality-and-treatment-of-infraorbital-hollowing-302942954.html) reported on November 18, 2026. The studies cover facial skin quality and infraorbital hollowing.\n\n## Somenek and Allen Lead the Two Studies\n\n[Lynch Regenerative Medicine](https://akta.pro/company-profiles/00031g2/lynch-regenerative-medicine) is a Franklin, Tennessee-based regenerative medicine company founded in 2023 that commercializes three FDA-approved PDGF-BB products across wound care, dental bone grafting and medical aesthetics. The study led by Michael Somenek, MD, a double board-certified facial plastic surgeon, will examine the cellular effects of rhPDGF-BB injected into facial skin in 12 participants. Skin biopsies at 7 days, 14 days, 28 days or 8 weeks after injection will assess changes in gene and protein expression, including natural production of collagen, elastin and other extracellular matrix components. Completion is anticipated in Q2 2027.\n\nThe study led by Sarah Allen, MD, a double board-certified physician, Chief Medical Officer and Founder of Skin Clique, will evaluate the safety and efficacy of undereye injections of rhPDGF-BB for infraorbital hollowing in 30 participants. It will assess skin quality, the appearance of tear trough deformity and dark shadows, and the thickness, smoothness and brightness of under-eye skin 12 weeks after injection. Completion is anticipated in Q3 2027.\n\n\"Dr. Somenek's study will further elucidate the mechanism of action of pure PDGF when injected specifically into facial skin, while Dr. Allen's study will complement LRM's ongoing Phase 2 multi-center trial for treatment of IOH,\" said Dr. Samuel Lynch, Founder and Chief Executive Officer of Lynch Regenerative Medicine. Allen said platelet-derived growth factor has been used for decades in orthopedics, oral and maxillofacial surgery and wound care. \"Infraorbital hollowing is one of the most common concerns patients bring to us, yet treatment options have changed very little in more than two decades,\" she said.\n\n## Funding and Corporate Structure Behind the Program\n\nAccording to akta.pro [company records](https://akta.pro/company-data), Lynch Regenerative Medicine has raised total funding of $22.5 million at Series A stage, with the last round on July 15, 2026. The records list a $15 million round in July 2026, a $3.8 million Series A led by Champion VC in July 2024 and a $3.8 million round in January 2024. In March 2026 the company announced a dual-arm structure creating LRM Aesthetics, Inc. and LRM Therapeutics, Inc.\n\n## Earlier FDA Clearance and Trial Milestones\n\nIn October 2026, the FDA authorized Lynch Regenerative Medicine's IND for a Phase IIb clinical trial of injectable rhPDGF-BB for treatment of infraorbital hollowing, PR Newswire reported. In August 2026, enrolment concluded in a Phase II trial of rhPDGF-BB for surgical wounds after skin cancer excision, Clinical Trials Arena reported; the study enrolled 34 patients, comparing an rhPDGF-BB-enhanced collagen matrix to a saline-treated control with eight-week follow-up.\n\n## What Comes Next for the Two Trials\n\nThe Somenek study is anticipated to complete in Q2 2027 and the Allen study in Q3 2027, according to the company's [announcement](https://www.lynchregen.com).\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}